Clinical Trial Update: Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating daratumumab to overcome platelet transfusion refractoriness in patients with aplastic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Platelet Transfusion Refractoriness

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Aplastic Anemia, Platelet Transfusion Refractoriness | Phase 1 | Status: COMPLETED